A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer

Reshma Mahtani; Frankie Ann Holmes; Sunil Badve; Humberto Caldera; Robert Coleman; Eleftherios Mamounas; Kevin Kalinsky; Muaiad Kittaneh; Elyse Lower; Mark Pegram; Michael F Press; Hope S. Rugo; Lee Schwartzberg; Charles L. Vogel; Breast Cancer Therapy Expert Group (BCTEG)

A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer

Reshma Mahtani, Frankie Ann Holmes, Sunil Badve, Humberto Caldera, Robert Coleman, Eleftherios Mamounas, Kevin Kalinsky, Muaiad Kittaneh, Elyse Lower, Mark Pegram, Michael F Press, Hope S. Rugo, Lee Schwartzberg, Charles L. Vogel, Breast Cancer Therapy Expert Group (BCTEG)

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Clinical Breast Cancer
Volume	20
State	Published - 2020

Disciplines

Medicine and Health Sciences

Cite this

Mahtani, R., Holmes, F. A., Badve, S., Caldera, H., Coleman, R., Mamounas, E., Kalinsky, K., Kittaneh, M., Lower, E., Pegram, M., Press, M. F., Rugo, H. S., Schwartzberg, L., Vogel, C. L., & (BCTEG), B. C. T. E. G. (2020). A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clinical Breast Cancer, 20.

Mahtani, R, Holmes, FA, Badve, S, Caldera, H, Coleman, R, Mamounas, E, Kalinsky, K, Kittaneh, M, Lower, E, Pegram, M, Press, MF, Rugo, HS, Schwartzberg, L, Vogel, CL & (BCTEG), BCTEG 2020, 'A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer', Clinical Breast Cancer, vol. 20.

@article{fe623e2063c24159adbec1e155e1fde2,

title = "A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer",

author = "Reshma Mahtani and Holmes, \{Frankie Ann\} and Sunil Badve and Humberto Caldera and Robert Coleman and Eleftherios Mamounas and Kevin Kalinsky and Muaiad Kittaneh and Elyse Lower and Mark Pegram and Press, \{Michael F\} and Rugo, \{Hope S.\} and Lee Schwartzberg and Vogel, \{Charles L.\} and (BCTEG), \{Breast Cancer Therapy Expert Group\}",

note = "Expression of human epidermal growth factor receptor 2 (HER2) in breast cancer defines a subset of patients (∼15\%-20\%) who are candidates for anti-HER2 therapies, most notably, trastuzumab, pertuzumab, antibody drug conjugates (eg, T-DM1), and tyrosine kinase inhibitor (TKI) drugs (eg, lapatinib and ...",

year = "2020",

language = "American English",

volume = "20",

journal = "Clinical Breast Cancer",

}

TY - JOUR

T1 - A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer

AU - Mahtani, Reshma

AU - Holmes, Frankie Ann

AU - Badve, Sunil

AU - Caldera, Humberto

AU - Coleman, Robert

AU - Mamounas, Eleftherios

AU - Kalinsky, Kevin

AU - Kittaneh, Muaiad

AU - Lower, Elyse

AU - Pegram, Mark

AU - Press, Michael F

AU - Rugo, Hope S.

AU - Schwartzberg, Lee

AU - Vogel, Charles L.

AU - (BCTEG), Breast Cancer Therapy Expert Group

N1 - Expression of human epidermal growth factor receptor 2 (HER2) in breast cancer defines a subset of patients (∼15%-20%) who are candidates for anti-HER2 therapies, most notably, trastuzumab, pertuzumab, antibody drug conjugates (eg, T-DM1), and tyrosine kinase inhibitor (TKI) drugs (eg, lapatinib and ...

PY - 2020

Y1 - 2020

UR - https://pubmed.ncbi.nlm.nih.gov/32139271/

M3 - Article

VL - 20

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

ER -

A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer

Disciplines

Other files and links

Cite this